Across the UK, a critical shortage of the drug Nabilone is leaving patients with multiple sclerosis (MS) and other chronic conditions in severe distress. Jill Kenning, a patient from Northern Ireland who has relied on Nabilone for nearly two decades, describes the agonizing pain she endures without it as being “stabbed with a hot poker.” Her story highlights a growing crisis in the UK’s pharmaceutical supply chain that is forcing patients to endure unbearable suffering and hospitals to manage escalating complications.
How a Drug Shortage Is Amplifying Patient Suffering
Jill Kenning’s experience is a stark illustration of the human cost behind the numbers. Diagnosed with MS in 2008, Kenning has depended on Nabilone—a synthetic cannabinoid used to manage neuropathic pain—for 17 years. The medication has been pivotal in controlling her symptoms, enabling her to maintain a semblance of normal life despite the relentless progression of MS. Since running out of her prescription last week, she has been confined mostly to bed, battling intense pain and the side effects of substitute medications that have proven ineffective.
Kenning’s case is not isolated. The UK is currently facing a surge in drug shortages, with the number of medicines in short supply rising from 107 in January to 157 this week, according to data from the industry reference guide MIMS. This trend signals a systemic issue that stretches beyond one medication or one condition, affecting thousands of patients who rely on consistent access to essential therapies.
Behind the Shortage: Supply Chain and Commercial Challenges
The Northern Ireland Department of Health has confirmed that both licensed doses of Nabilone—1mg and 0.25mg capsules—are out of stock across the UK, with the shortage first impacting the higher dose in July. While officials are collaborating with the UK Department of Health and Social Care and local health trusts to manage the disruption, they have declined to disclose the exact reasons behind the shortage, citing “commercially sensitive” information.
Experts suggest several factors could be contributing to the scarcity. These include manufacturing delays, supply chain disruptions exacerbated by Brexit and the COVID-19 pandemic, and market dynamics such as limited production incentives for niche or older drugs. Nabilone, while crucial for some patients, may not be a high-volume product, making it vulnerable to supply interruptions that are harder to resolve quickly.
Consequences for Patients and Healthcare Providers
The immediate impact of the shortage is painfully clear in patients like Kenning, who report unrelenting pain, loss of sleep, nausea, and declining overall health. Unable to access the drug that has managed their symptoms for years, many patients face deteriorating quality of life and increased hospitalizations. Kenning herself was admitted to hospital for several nights due to the severity of her condition after alternative medications failed.
Healthcare professionals are also caught in a difficult position. The Department of Health has issued guidance on alternative treatments, including the possibility of unlicensed imports of Nabilone, but these options are often limited and may not provide the same efficacy or safety profile. Clinicians must balance the urgency of symptom control with the uncertainties around substitute therapies, all while managing patient anxiety and frustration.
Wider Implications for the UK’s Medicine Supply System
The Nabilone shortage shines a spotlight on a broader, escalating issue within the UK’s pharmaceutical supply chain. The increasing frequency of drug shortages—now at a record high—raises concerns about the resilience of the system to safeguard access to essential medicines. This challenge is compounded by the complex interplay of global supply chain vulnerabilities, regulatory changes, and market pressures.
For patients with chronic and complex conditions like MS, consistent access to medications is not a luxury but a necessity that directly affects their ability to function and live with dignity. Interruptions can lead to worsening symptoms, increased healthcare costs, and emotional distress. The current crisis underscores the need for more robust monitoring, contingency planning, and transparency from manufacturers and health authorities.
What Needs to Change to Prevent Future Crises?
Addressing drug shortages requires coordinated action across multiple levels. Firstly, improved transparency from pharmaceutical companies about supply issues could enable earlier intervention and better patient preparedness. Secondly, investment in domestic manufacturing capabilities may reduce reliance on fragile international supply chains. Thirdly, health systems need to develop rapid-response frameworks to provide effective alternative therapies and support for patients during shortages.
For patients like Jill Kenning, these changes cannot come soon enough. As she struggles with unbearable pain and uncertainty, her story is a call to action for policymakers, healthcare providers, and industry stakeholders to prioritize medicine availability as a critical component of patient care and public health.
Recommended reading
For more context, see related Peack News coverage and explainers linked below.